PMU12 Cost-Benefit Analysis of Sodium Glucose Cotransporter-2 Inhibitor Use for Patients <65 Years with Type 2 Diabetes and Heart Failure with Reduced Ejection Fraction
2021
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI